Is there a need for recombinant human luteinizing hormone (lutropin alfa) supplementation in ovarian stimulation for assisted reproduction?

Women's Health

Volumn 2, Issue 3, 2006, Pages 375-384

  Nawroth, Frank ^a   Ludwig, Michael ^a  

^a ENDOKRINOLOGIKUM HAMBURG   (Germany)

Author keywords

Gonadotropin; Hypogonadism; Hypogonadotrophic; Lutropin alfa; Ovarian stimulation; Poor response; Recombinant technology

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; LUTROPIN ALFA; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; FEMALE; FEMALE INFERTILITY; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; OOCYTE MATURATION; OVARY FOLLICLE DEVELOPMENT; OVARY FOLLICLE MATURATION; OVULATION INDUCTION; PREGNANCY RATE; SPONTANEOUS ABORTION; WORLD HEALTH ORGANIZATION;

EID: 33646793005     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.3.375     Document Type: Article

References (69)

1. Howles CM: Role of LH and FSH in ovarian function. Mol. Cell. Endocrinol. 161, 25-30 (2000).
2. Gougeon A: Dynamics of follicular growth in the human: a model from preliminary results. Hum. Reprod. 1, 81-87 (1986).
3. Oktay K, Newton H, Mullan J, Gosden RG: Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone. Hum. Reprod. 13, 1133-1138 (1998).
4. Ryan KJ, Petro Z: Steroid biosynthesis by human ovarian granulosa and theca cells. J. Clin. Endocrinol. Metab. 26, 46-52 (1966).
5. Erickson GF, Wang C, Hsueh AJ: FSH induction of functional LH receptors in granulosa, cells cultured in a chemically defined medium. Nature 279, 336-338 (1979).
6. Shima K, Kitayama S, Nakano R: Gonadotropin binding sites in human ovarian follicles and corpora lutea during the menstrual cycle. Obstet. Gynecol. 69, 800-806 (1987).
7. Hillier SG, Whitelaw PF, Smyth CD: Follicular oestrogen synthesis: the 'two-cell, two-gonadotrophin' model revisited. Mol. Cell. Endocrinol. 100, 51-54 (1994).
8. Filicori M. Cognigni GE, Pocognoli P. Ciampaglia W. Bernardi S: Current concepts and novel applications of LH activity in ovarian stimulation. Trends Endocrinol. Metab. 14, 267-273 (2003).
9. Adams J, Polson DW. Abdulwahid N et al.: Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 2. 1375-1379 (1985).
10. Glueck CJ, Phillips H, Cameron D. Sieve-Smith L, Wang P: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil. Steril. 75, 46-52 (2001).
11. Howles CM, MacNamee MC: The endocrinology of stimulated cycles and influence on outcome. In: Advances in Assisted Reproductive Technologies. Mashiach S (Ed). Plenum Press, NY, USA, 311-325 (1990).
12. Hillier SG: Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum. Reprod. 9, 188-191 (1994).
13. Shoham Z: Treatment of female infertility with recombinant human luteinizing hormone: is there a benefit over other available drugs? Expert Opin. Pharmacother. 4, 1985-1994 (2003).
14. Balasch J. Fabregues F: Is luteinizing hormone needed for optimal ovulation induction? Curr. Opin. Obstet. Gynecol. 14, 265-274 (2002).
15. Stanger JD, Yovich JL: Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br. J. Obstet, Gynaecol. 92, 385-393 (1985).
16. Howles CM, Macnamee MC, Edwards RG, Goswamy R, Steptoe PC: Effect of high tonic levels of luteinising hormone on outcome of in-vitro fertilisation. Lancet 30, 521-522 (1986).
17. Tesarik J, Mendoza C: Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum. Riprod. 17, 3129-3137 (2002).
18. The European Recombinant Human LH Study Group: Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J. Clin. Endcrinol. Metab. 83, 1507-1514 (1998).
19. Loumaye E. Engrand P. Shoham Z. Hillier SG, Baird DT: Clinical evidence for an LH "ceiling" effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum. Reprod. 18, 314-322 (2003).
20. Hugues JN. Soussis J. Calderon I. Balasch J. Anderson RA. Romeu A. Recombinant LH Study Group: Does the addition of recombinant LH on WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum. Reprod. 20, 629-635 (2005).
21. Filicori M. Cognigni GE. Ferlini F et al.: Prospective, randomized, dose finding study of human chorionic gonadotropin (hCG) administration in controlled ovarian stimulation (COS). Hum. Reprod. 20(Suppl. 1), S64-S65 (2005).
22. Filicori M. Cognigni GE. Gamberini E. Parmigiani L. Trallo E. Roset B: Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil. Steril. 84, 394-401 (2005).
23. Stokman PG. de Leeuw R. van den Wijngaard HA. Kloosterboer HJ. Verner HM. Sanders AL: Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil. Steril. 60, 175-178 (1993).
24. Balasch J. Miro F. Burzaco I et al.: The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle-stimulating hormone. Hum. Reprod. 10, 1678-1683 (1995).
25. Hull M. Corrigan E. Piazzi A. Loumaye E: Recombinant human luteinising hormone: an effective new gonadotropin preparation. Lancet 344, 334-335 (1994).
26. Fleming R. Rehka P. Deshpande N. Jamieson ME. Yates RW. Lyall H: Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum. Reprod. 15, 1440-1445 (2000).
27. Daya S. Gunby J: Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Hum. Reprod. 14, 2207-2215 (1999).
28. Daya S: Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro ferilization and gamete intrafallopian transfer cycles. Cochrane Database Syst. Rev. 2, CD001299 (2000).
29. Fleming R. Lloyd F. Herbert M. Fenwick J. Griffiths T. Murdoch A: Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activitiy,. oocyte and embryo function in cycles stimulated with with purified follicle stimulating hormone. Hum. Reprod. 13, 1788-1792 (1998).
30. Westergaard LG, Laursen SB, Andersen CY: Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum. Reprod. 15, 1003-1008 (2000).
31. Esposito MA. Barnhart KT. Coutifaris C. Patrizio P: Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil. Steril. 75, 519-524 (2001).
32. Fanchin R. Schönauer L. Righini C. Olivennes F. Taieb J. Frydman F: Beneficial effects of residual LH levels after GnRH agonist on ovarian response to r-FSH, embryo quality, and IVF-ET outcome. Fartil. Steril. 76(Suppl. 1), S91 (2001).
33. Balasch J. Vidal E. Penarrubia J et al.: Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Hum. Reprod. 16, 1636-1643 (2001).
34. Humaidan P. Bungum L. Bungum M. Andersen CY: Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum. Reprod. 17, 2016-2021 (2002).
35. Chappel SC. Howles C: Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum. Reprod. 6, 1206-1212 (1991).
36. Balasch J. Creus M. Fabregues F et al.: The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction. J. Assist. Reprod. Genet. 18, 250-256 (2001).
37. Ho JYP, Guu HF, Chen MJ, Ho ESC: The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders". Fertil. Steril. 83, 883-888 (2005).
38. Liu SY, Han JI, Peng XD. Dong X. Xu J, Yan JM: Effect of midfollicular luteinizing hormone levels on ovarian response and pregnancy outcome in patients undergoing in vitro fertilization in a short-term protocol. Fertil. Steril. 83, 1043-1046 (2005).
39. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C: The ovarian androgen producing cells: a review of structure/function relationships. Endocr. Rev. 6, 371-399 (1985).
40. Lisi F, Rinaldi R, Fishel S, Lisi R, Pepe G, Picconeri MG: Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study. Reprod. Biomed. Online 3, 190-194 (2001).
41. De Placido G. Mollo A, Alviggi C et al.: Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum. Reprod. 16, 1875-1879 (2001).
42. Ferraretti AP, Gianaroli L, Magli MC, D'angelo A, Farfalli V, Montanaro N: Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil. Steril. 82, 1521-1526 (2004).
43. Marrs R, Meldrum D, Muasher S, Schollcraft W, Werlin L, Kelly E: Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod. Biomed. Online 8, 175-182 (2004).
44. Humaidan P, Bungum L, Bungum M, Yding Andersen C: Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinaint FSH: an opening study Reprod. Biomed. Online 8, 635-643 (2004).
45. Sills ES, Levy DP, Moomjy M, McGee M, Rosenwaks Z: A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro, fertilization. Hum. Reprod. 14, 2230-2235 (1999).
46. Tarlatzis B, Tavmergen E, Szamatowicz M et al.: The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum. Reprod. 21, 90-94 (2006).
47. Drakakis P, Loutradis D, Kailianidis K et al: Small doses of LH activity are needed early in ovarian stimulation for better quality oocytes in IVF-ET. Eur. J. Obstet. Gynecol. Reprod. Biol. 121, 77-80 (2005).
48. Robertson DM, Burger HG: Reproductive hormones: ageing and the perimenopause. Acta Obstet. Gynecol. Scand. 81, 612-616 (2002).
49. Vihko KK, Kujansuu E, Morsky P, Huhtaniemi I, Punnonen R: Gonadotropins and gonadotropin receptors during the perimenopause. Eur. J. Endocrinol. 134, 357-361 (1996).
50. Mitchell R, Hollis S. Rothwell C, Robertson WR: Age related changes in the pituitary-testicular axis in normal men; lower serum testosterone results from decreased bioactive LH drive. Clin. Endcrinol. (Oxf.) 42, 501-507 (1995).
51. Huhtaniemi IT, Pettersson KS: Alterations in gonadal steroidogenesis in individuals expressing a common genetic variant of luteinizing hormone. J. Steroid Biochem. Mol. Biol. 69, 281-285 (1999).
52. Jiang M, Pakarinen P, Zhang FP et al: A common polymorphic allele of the human luteinizing hormone beta-subunit gene: additional mutations and differential function of the promoter sequence. Hum. Mol. Genet. 8, 2037-2046 (1999).
53. Ropelato MG, Garcia-Rudaz MC, Castro-Fernandez C et al.: A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 84, 4629-4636 (1999).
54. Piltonen T, Kolvunen R, Ruokonen A, Tapanainen JS: Ovarian age-related responsiveness to human chorionic gonadotropin. J. Clin. Endocrinol. Metab. 88, 3327-3332 (2003).
55. Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell JA, Balasch J: Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil. Steril. 85(4), 925-931 (2006).
56. Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE: Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil. Steril. 76, 543-549 (2001).
57. De Placido G, Alviggi C, Mollo A et al.: Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin. Endocrinol. (Oxf.) 60, 637-643 (2004).
58. De Placido G, Alviggi C, Perino A et al.: Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotropic women with initial inadequate response to rFSH. A multicentre, prospective, randomized controlled trial. Hum. Reprod. 20, 390-396 (2005).
59. Alviggi C, Pettersson K, Mono A et al.: Impaired multiple follicular development in carriers of Trp8Arg and Ile15Thr LH-beta variant undergoing controlled ovarian stimulation. Hum. Reprod. 20(Suppl. 1). S139-S140 (2005).
60. Foong SC, Abbott DH, Lesnick TG, Session DR, Walker DL, Dumesic DA: Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone. Fertil. Steril. 83, 1377-1383 (2005).
61. Tesarik J, Hazout A, Mendoza C: Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod. Biomed. Online 7, 59-64 (2003).
62. Kolibianakis EM, Zikopoulos K, Schiettecatte J et at.: Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum. Reprod. 19, 2490-2496 (2004).
63. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A et al.: Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum. Reprod. 19, 1979-1984 (2004).
64. Sauer MV. Thornton MH II, Schoolcraft W, Frishman GN: Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reprod. Biomed. Online 9. 487-493 (2004).
65. Griesinger G. Schultze-Mosgau A, Dafopoulos K et al.: Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose, protocol. Hum. Reprod. 20, 1200-1206 (2005).
66. De Placido G, Mollo A, Clarizia R, Strina I, Conforti S, Aiviggi C: Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinzing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertil. Steril. 85, 247-250 (2006).
67. Balen AH, Mulders AG, Fauser BC et al.: Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. J. Clin. Endocrinol. Metab. 89, 6297-6304 (2004).
68. Behre HM, Greb RR, Mempel A et al.: Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet. Genomics 15, 451-456 (2005).
69. Greb RR, Grieshaber K, Gromoll J et al.: A common single nucleotide polymorphism in exon 10 of the human follicle stimulating hormone receptor is a major determinant of length and hormonal dynamics of the menstrual cycle. J. Clin. Endocrinol. Metab. 90, 4866-4872 (2005).